Regional chemotherapy in the treatment of advanced pancreatic cancer - Is it relevant?

European Journal of Cancer

Volumn 36, Issue 8, 2000, Pages 957-965

  Lorenz, M ^a   Heinrich, S ^a   Staib Sebler, E ^a   Kohne C H ^b   Wils, J ^c   Nordlinger, B ^d   Encke, A ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^c LAURENTIUS HOSPITAL   (Netherlands)

^d HÔPITAL AMBROISE PARÉ   (France)

Author keywords

Aortic stop flow; Celiac axis infusion; Isolated hypoxic perfusion; Pancreatic cancer; Regional chemotherapy

Indexed keywords

CISPLATIN; CYTOSTATIC AGENT; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; MICROSPHERE; MITOMYCIN C; MITOXANTRONE; TUMOR MARKER;

ABDOMINAL AORTA; ANGIOGRAPHY; ARTIFICIAL EMBOLISM; BALLOON CATHETER; CELIAC ARTERY; CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG TUMOR LEVEL; HEMOFILTRATION; HUMAN; HYPOXEMIA; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURVIVAL TIME; TECHNIQUE;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; HUMANS; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 0034106161     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00073-3     Document Type: Review

References (37)

1. Warshaw A.L., Fernandez-del Castillo C. Pancreatic carcinoma. N. Engl. J. Med. 326:1992;455-465.
2. Lillemoe K.D. Current management of pancreatic carcinoma. Ann. Surg. 221:1995;133-148.
3. Black R.J. Cancer incidence and mortality in the European Union. cancer registry data and estimates of national incidence for 1990 Eur. J. Cancer. 33(7):1997;1075-1107.
4. Hunstad D.A., Norton J.A. Management of pancreatic carcinoma. Surg. Oncol. 4:1995;61-74.
5. Ahlgren J.D. Chemotherapy for pancreatic carcinoma. Cancer. 78:1996;654-663.
6. Burris H.A., Moore M.J., Andersen J.et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer. a randomized trial J. Clin. Oncol. 15(6):1997;2403-2413.
7. Scheithauer W. Current status of chemotherapy for pancreatic cancer. possibilities and limitations Wien. Klin. Wochenschr. 106:1994;704-708.
8. Hryniuk W.M., Figueredo A., Goodyear M. Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin. Oncol. 15(Suppl. 4):1987;3-11.
9. Lorenz M., Staib-Sebler E., Gog C., Vetter G., Petrowsky H., Müller H.H. Liver metastases. the value of regional long-term chemotherapy Chirurg. 70:1999;141-153.
10. Collins J.M. Pharmacologic rationale for regional drug delivery. J. Clin. Oncol. 2(5):1984;498-504.
11. Donatini B., Rougier P. Anatomical basis for pancreatic locoregional chemotherapy. Reg. Cancer Treat. 4:1992;272-276.
12. Ensminger W.D., Gyves J.W., Stetson P., Walker-Andrews S. Phase I study of hepatic arterial degradable starch microspheres and mitomycin. Cancer Res. 45:1985;4464-4467.
13. Teicher B.A., Lazo J.S., Sartorelli A.C. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res. 41:1981;73-81.
14. Heinemann V., Schalhorn A., Schulz L.et al. Pharmacokinetics of gemcitabine in patients with advanced pancreatic cancer. Onkologie. 20(Suppl. 1):1997;56.
15. 14C-labeled mitomycin C. J. Surg. Res. 59:1995;415-419.
16. Arredondo M.A., Thomford N.R., Chaudhuri B., Chaudhuri P.K. Pharmacokinetics and tissue uptake of mitomycin C in isolated perfusion of pancreas. J. Surg. Res. 46:1989;445-449.
17. Arredondo M.A., Chaudhuri B., Kar R., Crist K.A., Thomford N.R., Chaudhuri P.K. Isolated perfusion of the pancreas with mitomycin C. Am. J. Surg. 159:1990;569-574.
18. Petrowsky H., Heinrich S., Janshon G.et al. Technik und Pathophysiologie der isolierten hypoxischen Perfusion des Abdomens. Zentralbl. Chir. 124:1999;833-839.
19. Hönl H, Ridwelski K, Mertens U, Lippert H. Pharmacokinetic aspects of mitomycin C in the aortic stop flow treatment. Reg Cancer Treat 1997, Suppl. 1, 14.
20. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting about results of cancer treatment. Cancer. 47:1981;207-214.
21. Haskell C.M. Cancer Treatment. 4th edn. 1995;WB Saunders, Philadelphia. 1164-1169.
22. Hafström L., Ihse I., Jönsson P.E., Lunderquist A., Stridbeck H. Intraarterial 5-FU infusion with or without oral testolactone treatment in irresectable pancreatic cancer. Acta. Chir. Scand. 146:1980;445-448.
23. Smith L., Gazet J.C. Intra-arterial chemotherapy for patients with inoperable carcinoma of the pancreas. Ann. Royal Coll. Surg. Engl. 62:1980;208-212.
24. Theodors A., Bukowski R.M., Hewlett S., Livingston R.B., Weick J.K. Intermittent regional infusion of chemotherapy for pancreatic adenocarcinoma. Am. J. Oncol. 5:1982;555-558.
25. Aigner K.R., Müller H., Bassermann R. Intra-arterial chemotherapy with MMC, CDDP and 5-FU for non-resectable pancreatic cancer - a phase II study. Reg. Cancer Treat. 3:1990;1-6.
26. Link K.H., Gansauge F., Görich J., Leder G.H., Rilinger N., Beger H.G. Palliative and adjuvant regional chemotherapy in pancreatic cancer. Eur. J. Surg. Oncol. 23:1997;409-414.
27. Gansauge F., Link K.H., Rilinger N., Kunz R., Beger H.G. Regional chemotherapy in advanced pancreatic carcinoma. Med. Klin. 90:1995;501-505.
28. Maurer C.A., Borner M.M., Lãuffer J.et al. Celiac axis infusion chemotherapy in advanced nonresectable pancreatic cancer. Int. J. Pancreatol. 23(3):1998;181-186.
29. Gebauer T, Ridwelski K, Fahlke J, Lippert H. Locoregional and systemic therapy in advanced pancreatic carcinoma. Langenbecks Arch Chir 1998, Suppl. 2, 1344-1347.
30. Klapdor R., Lang E.M., Seutter R., Reichle H., Hinrichs A. Advanced pancreatic cancer - locoregional chemotherapy with mitomycin C+gemcitabine. J. Cancer Res. Clin. Oncol. 124:1998;R11.
31. Muchmore J.H. Treatment of advanced pancreatic cancer with regional chemotherapy plus hemofiltration. Semin. Surg. Oncol. 11:1995;154-167.
32. Aigner K.R. Regional chemotherapy - editorial review article. Reg. Cancer Treat. 2:1994;55-66.
33. Fiorentini G., Poddie D., Ricci S.et al. Intra-aortic stop-flow infusion (IASFI) with hypoxic abdominal perfusion (HAP) in UICC stage III/IV pancreatic carcinoma (PC). report of a phase II study Reg. Cancer Treat. 9:1996;88-91.
34. Lorenz M., Petrowsky H., Heinrich S.et al. No benefit of isolated hypoxic perfusion with mitomycin C in patients with advanced pancreatic cancer. Eur. J. Surg. Oncol. 24:1998;542-547.
35. Beger H.G., Gansauge F., Büchler M.W., Link K.H. Intra-arterial adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic cancer. significant reduction in occurrence of liver metastasis World J. Surg. 23:1999;946-949.
36. Rothenberg M.L., Abbruzzese J.L., Moore M., Portenoy R.K., Robertson J.M., Wanebo H.J. A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer. 78(3):1996;627-632.
37. Aigner K.R., Gailhofer S., Kopp S. Regional versus systemic chemotherapy for advanced pancreatic cancer. a randomized study Hepato-Gastroenterology. 45:1998;1125-1129.